U.S. Software Stock News

The U.S. stock market has recently extended its gains, with major indices like the Dow Jones and Nasdaq showing positive momentum amid eased geopolitical tensions. In such a climate, investors often look beyond the well-known giants to explore opportunities in smaller or emerging companies. Penny stocks, though sometimes seen as relics of past market eras, continue to offer intriguing possibilities for those seeking affordability and potential growth. Here, we examine three penny stocks that...

Zions Bancorporation National Association (ZION) closed out FY 2025 with Q4 revenue of US$885 million and basic EPS of US$1.78, underpinned by net income of US$262 million as the bank reported its latest set of results. The company has seen revenue move from US$779 million and EPS of US$1.34 in Q4 FY 2024 to US$885 million and EPS of US$1.78 in Q4 FY 2025, setting up a story where investors are weighing higher earnings against how sustainable those margins look from here. See our full...

Aeva Technologies announced that Forterra has selected its 4D LiDAR sensors and perception technology to power AutoDrive, Forterra's autonomous defense vehicle system, enhancing obstacle detection and navigation in challenging, GPS-denied environments. This defense-focused win highlights how Aeva’s sensing platform is being applied in mission-critical, high-stakes use cases beyond traditional automotive autonomy. Next, we will assess how this Forterra selection shapes Aeva's investment...

First Citizens BancShares recently announced that it will report its latest quarterly earnings results on Friday morning, following a prior quarter in which it delivered US$2.25 billion of revenue, roughly flat compared with the same period a year earlier. An interesting aspect is that analysts have largely kept their earnings forecasts unchanged over the past month, signaling an expectation of business continuity rather than abrupt change heading into this report. With earnings around the...

If you are wondering whether RingCentral's current share price still reflects its true value, you are not alone, especially after years of sharp swings in sentiment. The stock closed at US$25.90, with returns of a 10.2% decline over the past week, 12.7% decline over the past month, and 6.1% decline year to date, adding to a 24.0% decline over 1 year and 31.0% decline over 3 years, while the 5 year return sits at a much larger 92.8% decline. These moves have come alongside ongoing investor...

Quite a few Enterprise Financial Services Corp ( NASDAQ:EFSC ) insiders sold their shares over the past year, which may...

PACS Group stock snapshot after recent performance moves PACS Group (PACS) has drawn fresh attention after a mixed recent performance, with a 1% gain in the latest session alongside a 9% decline over the past week and a month of modest softness. Over the past 3 months, the stock shows a very large total return, while the 1 year total return sits around 156%. Year to date, shares reflect a 9% decline, highlighting meaningful volatility for investors to weigh. See our latest analysis for PACS...

Q3 earnings beat and software push put Donnelley Financial Solutions (DFIN) in focus Donnelley Financial Solutions (DFIN) is back on investor radars after Q3 2025 earnings topped expectations and management outlined a plan to reach 60% of sales from software solutions by 2028. See our latest analysis for Donnelley Financial Solutions. The Q3 earnings beat and the push toward software have come alongside a 30 day share price return of 18.18% and a year to date share price return of 19.81%...

The simplest way to invest in stocks is to buy exchange traded funds. But one can do better than that by picking better...

Tango Therapeutics (TNGX) is in focus after founding CEO and President Dr. Barbara Weber retired, with board member Dr. Malte Peters stepping in as President and CEO, while she transitions to Executive Chair. See our latest analysis for Tango Therapeutics. The leadership change follows a period of strong price momentum, with Tango Therapeutics posting a 45.13% 1‑month share price return and a 66.14% 3‑month share price return, while its 1‑year total shareholder return is just over 3x. If this...

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

Investors may be wondering if Reynolds Consumer Products, at around US$24.28 a share, still offers solid value or if most of the opportunity is already reflected in the price. Over the short term, the stock has been fairly steady, with a 0.2% decline over 7 days, a 3.1% gain over 30 days, and a 5.3% return year to date. The 1 year return sits at an 8.7% decline, and the 3 and 5 year returns are 8.2% and 8.9% declines respectively. Recent attention on household and consumer staples companies...

Murphy Oil (NYSE:MUR) reported that its Civette-1X exploration well offshore Côte d'Ivoire encountered non-commercial hydrocarbons. The result, in Block CI-502, was announced as an early-stage outcome that will inform the company's international exploration efforts. Murphy Oil plans to focus next on the nearby Caracal and Bubale prospects in the same offshore area. Murphy Oil, an independent exploration and production company, is using this early result from Civette-1X as a data point for...

ServisFirst Bancshares (SFBS) capped FY 2025 with fourth quarter revenue of US$154.3 million and EPS of US$1.58, as trailing twelve month figures reached US$527.1 million in revenue and EPS of US$5.06. Over the past year, revenue has moved from US$458.7 million on a trailing basis to US$527.1 million, while EPS over the same period shifted from US$4.17 to US$5.06, providing additional context for how you might think about the bank’s earnings power. With a trailing net profit margin of 52.5%...

Charles Schwab FY 2025 Earnings Snapshot Charles Schwab (SCHW) closed FY 2025 with fourth quarter revenue of US$6.3 billion and basic EPS of US$1.34, alongside net income excluding extra items of US$2.4 billion, putting a solid set of headline numbers in front of investors. The company has seen quarterly revenue move from US$5.3 billion and EPS of US$0.94 in Q4 2024 to US$6.3 billion and EPS of US$1.34 in Q4 2025, alongside trailing twelve month EPS of US$4.67 and revenue of US$24.0 billion...

Earlier in January 2026, AtriCure issued 2026 revenue guidance of approximately US$600 million to US$610 million and amended its asset-based revolving credit facility, extending the term, lowering interest rates and maintaining up to US$125 million in borrowing capacity with the option to increase to US$165 million. Together, the higher revenue outlook and more flexible, lower-cost credit line highlight management’s confidence in AtriCure’s growth plans and liquidity position. Next, we’ll...

United Airlines FY 2025 Earnings Snapshot United Airlines Holdings (UAL) has wrapped up FY 2025 with Q4 revenue of US$15.4b and basic EPS of US$3.19, supported by net income of US$1,044m. Over recent quarters, the company has seen revenue move from US$14.7b in Q4 2024 to US$15.2b in Q3 2025 and US$15.4b in Q4 2025. Basic EPS over the same Q4 periods shifted from US$2.94 to US$3.19, setting up a results season where investors can weigh steady top line and earnings against how efficiently those...

Why Day One Biopharmaceuticals is in the spotlight Day One Biopharmaceuticals (DAWN) is back on investors’ radar after releasing preliminary 2025 OJEMDA revenue figures and issuing fresh 2026 guidance that ties directly to prescription and patient demand trends. The company reported unaudited OJEMDA net product revenue of approximately US$52.8 million for the fourth quarter of 2025 and US$155.4 million for the full year, with prescription volumes reaching 1,394 in the quarter. Management also...

In mid-January 2026, Sensata Technologies announced the launch of its STEV high-voltage contactor series, a scalable, customizable solution designed to improve safety, efficiency and integration across battery electric and plug-in hybrid vehicle platforms from passenger cars to heavy-duty trucks. A distinctive aspect of the STEV lineup is its combination of bidirectional current capability, hermetic ceramic sealing and global in-region manufacturing, positioning Sensata as a key enabler of...

Teledyne Technologies (TDY) has wrapped up FY 2025 with fourth quarter revenue of US$1.6b and basic EPS of US$5.60, alongside trailing twelve month revenue of US$6.1b and EPS of US$18.88 that frame the latest print in a broader earnings run. Over the past six quarters in the data, quarterly revenue has ranged from US$1.44b to US$1.61b, while basic EPS has moved between US$4.03 and US$5.61, giving investors a clear view of how the top and bottom lines have tracked together through recent...

If you are wondering whether Universal Technical Institute's share price still offers value after recent moves, it helps to step back and look at what the current market price might be implying. The stock last closed at US$28.15, with returns of 5.9% over the past week, 5.0% over the last month, 13.3% year to date, 6.1% over 1 year, and very large gains over 3 and 5 years. Recent attention on Universal Technical Institute has focused on its role in career and technical education, as...

Riverwater Partners recently highlighted IRADIMED CORPORATION as the top contributor to its Micro Opportunities Strategy in 2025, following record Q3 2025 revenue of US$21.2 million and FDA approval of the company’s MRI-compatible 3870 IV infusion pump in July 2025. Beyond the financial headlines, IRADIMED’s combination of accelerating revenue, new FDA-cleared technology and a special dividend, alongside insider share sales and a “Moderate Buy” analyst consensus, paints a complex picture of...

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Amongst other...

AbCellera Biologics (ABCL) has begun dosing patients in the Phase 2 portion of its Phase 1/2 trial for ABCL635, a potential first in class non hormonal treatment for menopausal vasomotor symptoms. See our latest analysis for AbCellera Biologics. The ABCL635 Phase 2 start comes as AbCellera’s 30 day share price return of 15.05% and year to date share price return of 24.78% contrast with a 3 year total shareholder return of 58.89% decline, suggesting sentiment has improved recently after a...